Oura’s latest partnership puts smart ring data directly in clinicians’ hands just as the FDA redraws the lines around wearable health tech
Oura has built a massive following by helping consumers obsess over sleep scores and recovery metrics. Now it wants clinicians in on the action.
The Finnish smart ring maker, now valued at roughly $11 billion, has partnered with Fullscript, a care platform used by providers and patients to manage diagnostic testing, build personalized supplement plans and order recommended products in one place.
With Oura in the mix, the smart ring’s biometric insights will be integrated into Fullscript’s platform, giving its more than 125,000 providers access to patients’ wearable data (including sleep, readiness and activity trends), provided patients opt in. From there, clinicians can use those insights to build a more comprehensive picture of health and help inform care decisions.
Kyle Braatz, Fullscript’s co-founder and CEO, says the partnership marks a major step in real-time, whole-person care.
“Oura’s continuous health signals are powerful on their own, but when paired with Fullscript’s clinical insights, lab data and personalized protocols, they become transformative,” he said. “Providers can now bring more context to treatment conversations and ongoing care management, allowing for more comprehensive care, all without leaving their existing workflow.”
The integration will roll out early this year, and by the second quarter, Oura’s smart ring will be available for clinicians to order directly through Fullscript’s catalog.
Midi Health is already leaning in. The celeb-backed virtual care platform, which focuses on women’s health and has dived into the supplement space, says it plans to bring Oura data into its provider workflows.
“Patients don’t just want more data — they want providers who can translate that data into care that feels personal, timely and relevant to their everyday lives,” Midi Health co-founder and CEO Joanna Strober said, adding that the integration will give Midi Health patients more tailored treatment plans and more meaningful follow-up.
Oura has tested this model before, partnering with Maven Clinic last year to bring biometric data into its virtual care platform for women’s health, intended to tailor guidance on fertility, pregnancy, and menopause.
Notably, the move comes as regulators are drawing clearer lines around what wearables can and can’t claim. Earlier this month, the Food and Drug Administration said it plans to limit oversight of low-risk wearables, fitness trackers and wellness apps, so long as they avoid making medical claims. In the case of Oura and Fullscript, the deal routes the wearable’s data through clinicians, keeping the consumer product on the “wellness” side while allowing providers to interpret the signals in a medical context.
Even so, Oura isn’t staying entirely on the sidelines. The wearable company says it’s actively working with the FDA as it develops new blood pressure features through Oura Labs. Oura has received Institutional Review Board approval for a validation study that will combine ring data with short user questionnaires to assess hypertension risk. Participants will receive classifications (ranging from no signs to major signs), and those flagged with stronger indicators will be encouraged to seek professional care.
During the ATN CEO Summit held last January, Hale spoke about Oura’s mission to transform the healthcare system, eyeing preventive care through wearables.
“Healthcare is oriented around is sick care,” Hale told the audience. “We know that the pharmaceutical industry has an incentive to get you sick. Why? Because they want you to buy their medicines. That’s the incentive of the industry, and I think we all in this room are focused on what is effectively some kind of preventative care, whether it’s for longevity, for health or for well-being.”
“Our view is that we can drive preventative care, and we can do that through a device,” he added.
For its part, Fullscript has also been sharpening its focus on supplement quality. Last month, the platform reaffirmed its Fullscript Quality Program, an initiative to tighten standards across its product catalog, from stricter brand vetting to third-party testing.
